文章基本信息

标题：Clonazepam Use for Prevention of Acute and Delayed Vomiting Induced by Cisplatin-Based Chemotherapy for Lung Cancer
本地全文：下载
作者：Masahiko Hayashi ; Yusuke Takao ; Chihiro Hata 等
期刊名称：Biological and Pharmaceutical Bulletin
印刷版ISSN：0918-6158
电子版ISSN：1347-5215
出版年度：2010
卷号：33
期号：11
页码：1907-1910
DOI：10.1248/bpb.33.1907
出版社：The Pharmaceutical Society of Japan
摘要：We investigated the efficacy of clonazepam as an antiemetic in cisplatin-based chemotherapy for lung cancer. Seven patients experienced cisplatin-induced vomiting despite antiemetic therapy including 5-hydroxytryptamine₃ (5-HT₃) antagonist and dexamethasone. Therefore, the antiemetic therapy including clonazepam, 5-HT₃ antagonist and dexamethasone was subsequently explored in the next course for the same seven patients. We administered clonazepam (0.5 or 1.0 mg/kg) once a day orally for 5 d from day one prior to chemotherapy. The grade of delayed vomiting, evaluated according to Common Terminology Criteria for Adverse Events Version 3.0, in the courses of therapy with clonazepam was significantly lower than without clonazepam ( p =0.013). The patients whose serum clonazepam concentrations were below the lower limit of detection (3.0 ng/ml) experienced vomiting in three of three courses, whereas the patients whose serum clonazepam concentrations were higher than 4.3 ng/ml experienced no vomiting in six of seven courses. We observed that the symptom of cisplatin-induced delayed vomiting is controlled with serum clonazepam levels in the order of 10.0 ng/ml.
关键词：antiemetic efficacy;clonazepam concentration;cisplatin-induced vomiting;lung cancer